Characterization of mixtures of recombinant human cytochrome P450s as a screening model for metabolic stability in drug discovery

References

• BAJPAI, M. and ADKISON, K. K., 2000, High-throughput screening for lead optimization: a rational approach. Current Opinions in Drug Discovery and Development, 3, 63–71.
   PubMedGoogle Scholar
• CRESPI, C. L. and MILLER, V. P., 1997, The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics, 7, 203–210.
   PubMedGoogle Scholar
• CRESPI, C. L. and MILLER, V. P., 1999, The use of heterologously expressed drug metabolizing enzymes — state of the art and prospects for the future. Pharmacology and Therapeutics, 84, 121–131.
   PubMed Web of Science ®Google Scholar
• CRESPI, C. L. and PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug—drug interactions. Advances in Pharmacology, 43, 171–188.
   PubMedGoogle Scholar
• DAI, D., TANG, J., ROSE, R., HODGSON, E., BIENSTOCK, R. J., MOHRENWEISER, H. W. and GOLDSTEIN, J. A., 2001, Identification of variants of CYP3A4 and characterization of their abilities to metabolise testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics, 299, 825–831.
   PubMed Web of Science ®Google Scholar
• EDDERSHAW, P. J. and DICKINS, M., 1999, Advances in in-vitro drug metabolism screening. Pharmaceutical Science and Technology Today, 2, 13–19.
   PubMedGoogle Scholar
• EISELT, R., DOMANSKI, T. L., ZIBAT, A., MUELLE R., PRESECAN-SIEDEL, E., HUSTERT, E., ZANGER, U. M., BROCKMOLLER, J., KLENK, H.P., MEYER, U. A., KHAN, K. K., HE, Y.A., HALPERT, J. R. and WOJNOWSKI, L., 2001, Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11,447–458.
   Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn (New York: Plenum), pp. 473–535.
   Google Scholar
• GUT, J., CATIN, T., DAYER, P., KRONBACH, T., ZANGER, U. and MEYER, U. A., 1986, Debrisoquine/ sparteine-type polymorphism of drug oxidation. Journal of Biological Chemistry, 261, 11734–11743.
   Google Scholar
• HOUSTON, J. B. and KENWORTHY, K. E., 2000, In vitro—in vivo scaling of CYP kinetic data not consistent with the classical Michaelis—Menten model. Drug Metabolism and Disposition, 28, 246–254.
   PubMed Web of Science ®Google Scholar
• INOUE, K., YAMAZAKI, H., ImiYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and CYP2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103–113.
   PubMedGoogle Scholar
• JONES, D. R., GORSKI, J. C., HAMMAN, M. A. and HALL, S. D., 1996, Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. Journal of Chromatography B, 678, 105–111.
   PubMed Web of Science ®Google Scholar
• JUNG, F., RICHARDSON, T. H., RAUCY, J. L. and JOHNSON, E. F., 1997, Diazepam metabolism by cDNA-expressed human 2C P450s. Drug Metabolism and Disposition, 25, 133–139.
   PubMed Web of Science ®Google Scholar
• KIUMURA, M., him, I., MAMIYA, K., URAE, A. and HiGuati, S., 1998, Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring, 20, 243–247.
   PubMed Web of Science ®Google Scholar
• KOHLER, D., HÁRTTER, S., FUCHS, K., SIEGHART, W. and HIEMKE, C., 1997, CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics, 7, 453–461.
   Google Scholar
• KORZEKWA, K. R., KRISHNAMACHARY, N., SHOU, M., OGAI, A., PARISE, R. A., RETTIE, A. E., GONZALEZ, F. J. and TRACY, T. S., 1998, Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry, 37, 4137–4147.
   PubMed Web of Science ®Google Scholar
• LANG, D. and BOCKE R., 1995, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P4502C9 activity. Journal of Chromatography B, 672, 305–309.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1998, The CYP2 family: models, mutants and interactions. Xenobiotica, 28, 617–661.
   PubMed Web of Science ®Google Scholar
• LI, D. N., PRITCHARD, M. P., HANLON, S. P., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1999, Competition between cytochrome P450 isozymes for NADPH-cytochrome P-450 oxidor-eductase affects drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 289, 661–667.
   PubMed Web of Science ®Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MCGINNITY, D. F., GRIFFIN, S. J., MOODY, G. C., VOICE, M., HANLON, S., FRIEDBERG, T. and RILEY, R. J., 1999, Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metabolism and Disposition, 27,1017–1023.
   PubMed Web of Science ®Google Scholar
• MCGINNITY, D. F., PARKER, A. J., SOARS, M. and RILEY, R. J., 2000, Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition, 28, 1327–1334.
   PubMed Web of Science ®Google Scholar
• MOODY, G. C., GRIFFIN, S. J., MATHER, A. N., MCGINNITY, D. F. and RILEY, R. J., 1999, Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53–75.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• PARKINSON, A., 1996, Biotransformation of xenobiotics. In C. D. Klaassen (ed.), CasarettDoull's Toxicology: The Basic Science of Poisons, 5th edn (New York: McGraw-Hill), pp. 113–186.
   Google Scholar
• PELKONEN, O., MAENP, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203–1253.
   PubMed Web of Science ®Google Scholar
• PRITCHARD, M. P., GLANCEY, M. J., BLAKE, J. A. R., GILHAM, D. E., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1998, Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8, 33–42.
   Google Scholar
• PRITCHARD, M. P., OSSETIAN, R., Li, D. N., HENDERSON, C. J., BURCHELL, B., WOLF, C. R. and FRIEDBERG, T., 1997, A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Archives of Biochemistry and Biophysics, 345, 342–354.
   PubMed Web of Science ®Google Scholar
• REINERINK, E. J., DOORN, L., JANSEN, E. H. and VAN TEASEL, A. A., 1991, Measurement of enzyme activities of cytochrome P-450 isoenzymes by high-performance liquid chromatographic analysis of products. Journal of Chromatography, 553, 233–241.
   PubMed Web of Science ®Google Scholar
• RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P-4502C9 in the etiology of (S)-warfarin—drug interactions. Chemical Research in Toxicology, 5, 54–59.
   PubMed Web of Science ®Google Scholar
• ROBERTS, S. A., 2001, High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica, 31, 557–589.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• VAN DER HOEVEN, T., 1984, Assay of hepatic micro somal testosterone hydroxylases by high performance liquid chromatography. Analytical Biochemistry, 138, 57–65.
   PubMed Web of Science ®Google Scholar
• VENKATAKRISHNAN, K., VON MOLTKE, L. L., COURT, M. H., HARMATZ, J. S., CRESPI, C. L. and GREENBLATT, D. J., 2000, Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metabolism and Disposition, 28, 1493–1504.
   PubMed Web of Science ®Google Scholar
• VERMILION, J. L. and COON, M. J., 1978, Purified liver microsomal NADPH-cytochrome P450 reductase. Journal of Biological Chemistry, 253, 2694–2704.
   PubMed Web of Science ®Google Scholar
• VOICE, M. W., ZHANG, Y., WOLF, C. R., BURCHELL, B. and FRIEDBERG, T., 1999, Effects of human cytochrome bs on CYP3A4 activity and stability in vivo. Archives of Biochemistry and Biophysics, 366, 116–124.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., VENKATAKRISHNAN, K., SCHMIDER, J., HARMATZ, J. S. and SHADER, R. I., 1998, Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. Journal of Pharmacy and Pharmacology, 50, 997–1004.
   PubMed Web of Science ®Google Scholar
• WHITE, R. E., 1998, Short- and long-term projections about the use of drug metabolism in drug discovery and development. Drug Metabolism and Disposition, 26, 1213–1216.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H. and SHIMADA, T., 1997, Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Archives of Biochemistry and Biophysics, 346, 161–169.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K. and SHIMADA, T., 1998, Roles of two allelic variants (Arg144Cys and 11e359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica, 28, 103–115.
   PubMed Web of Science ®Google Scholar